Pulmatrix is a clinical-stage biotechnology company focused on the discovery and development of inhaled therapeutic products intended to prevent and treat respiratory and other diseases. Co. designs and develops inhaled therapeutic products based on its dry powder delivery technology, inhaled Small Particles Easily Respirable and Emitted (iSPERSE), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles. iSPERSE powders can be used with dry powder inhaler technologies and can be formulated with a range of drug substances including small molecules and biologics. The PULM stock yearly return is shown above.
The yearly return on the PULM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PULM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|